Marcin Czerwinski/LinkedIn
Mar 28, 2026, 17:01
Marcin Czerwinski: Neutralizing Anti-AAV Antibodies in Hemophilia B Gene Therapy
Marcin Czerwinski, Professor at Hirszfeld Institute of Immunology and Experimental Therapy, shared a post on LinkedIn about a recent article by Radoslaw Kaczmarek, adding:
“Radoslaw (Radek) Kaczmarek just wrote a great commentary about neutralizing anti-AAV antibodies (NAbs) in hemophilia B therapy that can block transduction, thereby abolishing efficacy.
It seems that this is not the case…”
Title: Hemophilia B gene therapy: a NAb-solute barrier overcome by AAV5
Author: Radoslaw Kaczmarek
Read the Full Article on RPTH Journal
Stay updated with Hemostasis Today.
-
Mar 28, 2026, 16:56Sonia Wolf: Reproductive Outcomes in Women with Sickle Cell Disease
-
Mar 28, 2026, 16:42Kalpana Gupta Shekhawat: Low Ferritin and Its Impact on Dopamine Signaling
-
Mar 28, 2026, 16:34Seema Dawood: Acquired Platelet Dysfunction with Eosinophilia – Bleeding Despite Normal Platelet Count
-
Mar 28, 2026, 16:18Mohamed F Doheim: AI-Driven Stroke Triage Boosts Workflow and EVT Use Across Multicenter Network
-
Mar 28, 2026, 16:12Shameen Shazaib: Sample Transport and Storage – Maintaining Specimen Integrity
-
Mar 28, 2026, 16:11Heghine Khachatryan: From Limited Options to Transformative Care in Hemophilia
-
Mar 28, 2026, 16:10Anagha Harindranath: TranSegNet Highlights The Growing Importance of AI in Advancing Real-World Clinical Applications
-
Mar 28, 2026, 16:07Mariam Mahmoud Ali: Understanding Vascular Territories Is Key to Quickly Localizing Strokes on MRI
-
Mar 28, 2026, 16:02Paul Bolaji: We Developed REACT Criteria for Post-Stroke Recrudescence or The ”Decompensated Stroke”